| Drug Name |
Hexaminolevulinate hydrochloride |
| Drug ID |
BADD_D01069 |
| Description |
Hexaminolevulinate is an optical imaging drug. In solution form it is instilled intravesically for use with photodynamic blue light cystoscopy as an adjunct to white light cystoscopy. On May 28, 2010, the U.S. Food and Drug Administration (FDA) granted approval for hexaminolevulinate hydrochloride (Cysview for Intravesical Solution, Photocure ASA), as an optical imaging agent for use in combination with the Karl Storz Photodynamic Diagnostic D-Light C (PDD) System for cystoscopic detection of non-muscle invasive papillary cancer of the bladder for patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Hexaminolevulinate is manufactured under the brand Cysview® by Photocure ASA. In Europe, Hexaminolevulinate is marketed under the brand Hexvix®. |
| Indications and Usage |
Hexaminolevulinate is indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. |
| Marketing Status |
Prescription |
| ATC Code |
V04CX06 |
| DrugBank ID |
DB06261
|
| KEGG ID |
D04436
|
| MeSH ID |
C419924
|
| PubChem ID |
6433082
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
68225-068; 10511-3001 |
| Synonyms |
5-aminolevulinic acid hexyl ester | aminolevulinic acid hexylester | hexa ALA | hexyl-aminolevulinate | hexylaminolevulinate | ALA hexyl ester | 5-ALAHE | hexaminolevulinate | (14C)-hexaminolevulinate | hexaminolevulinate hydrochloride |
